D. Boral Capital Reiterates “Buy” Rating for Humacyte (NASDAQ:HUMA)

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $25.00 price target on the stock.

A number of other analysts have also recently commented on HUMA. BTIG Research restated a “buy” rating and set a $6.00 target price on shares of Humacyte in a report on Friday, November 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Humacyte in a report on Monday, December 29th. Wall Street Zen cut Humacyte from a “hold” rating to a “sell” rating in a report on Sunday, December 21st. Benchmark lowered their price objective on shares of Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, January 21st. Finally, HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of Humacyte in a research report on Monday, December 1st. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $8.14.

Humacyte Stock Performance

Humacyte stock traded up $0.27 during mid-day trading on Monday, reaching $1.21. The company’s stock had a trading volume of 22,042,703 shares, compared to its average volume of 5,214,151. The firm’s fifty day moving average price is $1.10 and its two-hundred day moving average price is $1.48. The company has a market capitalization of $225.66 million, a P/E ratio of -5.24 and a beta of 1.93. Humacyte has a 12-month low of $0.88 and a 12-month high of $4.28. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.90 and a current ratio of 1.62.

Humacyte (NASDAQ:HUMA) last announced its earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.03. The company had revenue of $0.75 million for the quarter, compared to the consensus estimate of $0.92 million. Sell-side analysts predict that Humacyte will post -1.27 EPS for the current fiscal year.

Hedge Funds Weigh In On Humacyte

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wealth Enhancement Advisory Services LLC acquired a new position in Humacyte during the 2nd quarter valued at about $49,000. Concurrent Investment Advisors LLC increased its stake in shares of Humacyte by 17.5% during the second quarter. Concurrent Investment Advisors LLC now owns 51,115 shares of the company’s stock worth $107,000 after purchasing an additional 7,615 shares in the last quarter. Vanguard Personalized Indexing Management LLC purchased a new position in Humacyte in the 2nd quarter valued at $30,000. CWM LLC lifted its stake in shares of Humacyte by 29,921.4% in the second quarter. CWM LLC now owns 43,531 shares of the company’s stock worth $91,000 after buying an additional 43,386 shares in the last quarter. Finally, Endowment Wealth Management Inc. lifted its stake in Humacyte by 5.1% in the 2nd quarter. Endowment Wealth Management Inc. now owns 109,458 shares of the company’s stock worth $229,000 after purchasing an additional 5,350 shares in the last quarter. Hedge funds and other institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.